epi-Canagliflozin

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: epi-Canagliflozin
• 英文别名: (2S,5S)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₄H₂₅FO₅S
• 分子量: 444.5
• InChiKey: XTNGUQKDFGDXSJ-YLLXYKFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Agent for treating retinopathy
  申请人：CARNA HEALTH SUPPORT LTD.

  公开号：US10821126B2

  公开（公告）日：2020-11-03

  It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.

  本发明旨在提供一种用于治疗和/或改善由葡萄糖引起的视网膜病变的制剂。它是一种治疗由葡萄糖引起的视网膜病变的药剂，其活性成分包括钠/葡萄糖共转运体2抑制剂（SGLT2抑制剂），以正常剂量使用，或以较低剂量使用，从而不降低血糖。
• PROCESS FOR THE PREPARATION OF CANAGLIFLOZIN
  申请人：MYLAN LABORATORIES LTD.

  公开号：US20170247359A1

  公开（公告）日：2017-08-31

  A process for the preparation of canagliflozin. The process may be effectively implemented on an industrial scale. Several compounds useful as intermediates for the synthesis of canagliflozin (Formula 4, Formula 4a, Formula 4b and Formula 5) are also disclosed. The process involves the reduction of the compound of formula 3 in the presence of a metal hydride and an organic solvent to obtain the compound of formula 4, converting this into a compound of formula 5 which in turn is converted into canagliflozin.
• AGENT FOR TREATING RETINOPATHY
  申请人：CARNA HEALTH SUPPORT LLC.

  公开号：US20190240243A1

  公开（公告）日：2019-08-08

  It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.
• COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER
  申请人：CORNELL UNIVERSITY

  公开号：US20210236501A1

  公开（公告）日：2021-08-05

  Described herein are compositions and methods for treating a disease or disorder associated with PI3K signaling. For example, such compositions can include use of modulators of glucose metabolism, use of at least one kinase in the insulin-receptor/PI3K/O AKT/mTOR pathway, and/or use of diet that influences the subjects metabolic state.